Shots:

• Union to receive $20M up front and is eligible to receive ~$247M in milestone along with royalties on sales of orismilast in China & holds the global rights for the product outside of China
• Innovent gets an exclusive license to research- develop and commercialize orismilast (PDE4 Inhibitor) in China- including participating and recruiting Chinese patients for global studies
• In P-IIa clinical studies- orismilast demonstrated a superior profile with improved efficacy and tolerability. The therapy has provided POC data orally in psoriasis or AD & is well suited to address the unmet needs of the patient populations

  | Ref: PR Newswire | Image: Innovent